Celldex Therapeutics, Inc.CLDXNASDAQ
Loading
Year-over-year research & development expense growth
3Y CAGR
+3.6%/yr
Annual compound
Percentile
P93
Near historical high
vs 3Y Ago
1.1x
Modest growth
Streak
1 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2025 | 49.86% |
| 2024 | 38.59% |
| 2023 | 43.46% |
| 2022 | 44.79% |
| 2021 | 40.16% |
| 2020 | -5.01% |
| 2019 | -35.78% |
| 2018 | -30.91% |
| 2017 | -6.38% |
| 2016 | 2.55% |